You are here

Investor Relations

Home

Jeffrey Leiden, Chairman, President and CEO

Date	Title and Summary
Toggle SummaryOct 16, 2018	Vertex to Announce Third Quarter 2018 Financial Results on October 24 BOSTON --(BUSINESS WIRE)--Oct. 16, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET . Webcasts
Toggle SummaryOct 10, 2018	CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease ZUG, Switzerland   and   BOSTON   and   CAMBRIDGE, Mass. ,   Oct. 10, 2018   (GLOBE NEWSWIRE) --   CRISPR Therapeutics  (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and   Vertex Pharmaceuticals Incorporated   (NASDAQ:VRTX) Other
Toggle SummaryOct 1, 2018	Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines - First-of-its-kind contract with the Danish pharmaceutical and procurement organization, Amgros, is effective from today - - Vertex also announces reimbursement in Austria for ORKAMBI ® (lumacaftor/ivacaftor) to treat patients ages 6 through 11 with two copies of the F508del mutation - LONDON General Business